SCHEMBL13288936

SCHEMBL13288936

Bc1cnn2c(NCc3ccc(CNS(=O)(=O)c4ccc(C(C)=O)cc4)cc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 6/20 0.50
▸ GSK3B P49841 5/20 0.46
▸ CYP19A1 P11511 1/20 0.43
▸ OPRM1 P35372 1/20 0.40
▸ OPRD1 P41143 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ POLB P06746 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ RAB9A P51151 1/20 0.37
▸ CCNA2 P20248 1/20 0.37
▸ CCNA1 P78396 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12954106 0.92 CYP19A1 (0.44) CDK2GSK3BCYP19A1OPRM1OPRD1
SCHEMBL13120697 0.91 CDK2 (0.63) CDK2GSK3BCYP19A1CCNA2CCNA1
SCHEMBL13289053 0.90 CDK2 (0.53) CDK2GSK3BPOLBMEN1KMT2A
SCHEMBL13289052 0.90 CDK2 (0.53) CDK2GSK3BCYP19A1POLBMEN1
SCHEMBL14545999 0.90 CDK2 (0.54) CDK2GSK3BPOLBALDH1A1CYP1A2
SCHEMBL14546000 0.89 CDK2 (0.53) CDK2GSK3BCYP19A1POLBALDH1A1
SCHEMBL12954278 0.85 CDK2 (0.52) CDK2GSK3BCYP19A1POLBMEN1
SCHEMBL13288973 0.84 CDK2 (0.48) CDK2GSK3BCYP19A1OPRM1OPRK1
SCHEMBL13288866 0.84 CDK2 (0.59) CDK2GSK3BMEN1KMT2ARAB9A
SCHEMBL13289141 0.82 CDK2 (0.53) CDK2GSK3BRAB9ACCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback